Huntington National Bank Sells 1,781 Shares of Solventum Co. (NYSE:SOLV)

Huntington National Bank trimmed its holdings in Solventum Co. (NYSE:SOLV) by 19.1% in the fourth quarter, Holdings Channel reports. The institutional investor owned 7,523 shares of the company’s stock after selling 1,781 shares during the quarter. Huntington National Bank’s holdings in Solventum were worth $497,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Geode Capital Management LLC increased its position in shares of Solventum by 3.4% during the fourth quarter. Geode Capital Management LLC now owns 3,460,405 shares of the company’s stock valued at $227,992,000 after buying an additional 112,686 shares during the period. National Bank of Canada FI increased its holdings in Solventum by 1,587.6% during the 4th quarter. National Bank of Canada FI now owns 67,977 shares of the company’s stock worth $4,491,000 after acquiring an additional 63,949 shares during the period. B. Metzler seel. Sohn & Co. AG lifted its stake in Solventum by 292.0% in the 4th quarter. B. Metzler seel. Sohn & Co. AG now owns 12,986 shares of the company’s stock worth $858,000 after purchasing an additional 9,673 shares in the last quarter. Wellington Management Group LLP boosted its holdings in Solventum by 22.7% in the 4th quarter. Wellington Management Group LLP now owns 8,504 shares of the company’s stock valued at $562,000 after purchasing an additional 1,571 shares during the period. Finally, O Shaughnessy Asset Management LLC grew its position in shares of Solventum by 16.4% during the 4th quarter. O Shaughnessy Asset Management LLC now owns 5,175 shares of the company’s stock valued at $342,000 after purchasing an additional 731 shares in the last quarter.

Analyst Ratings Changes

SOLV has been the topic of a number of recent analyst reports. The Goldman Sachs Group increased their price objective on Solventum from $63.00 to $71.00 and gave the stock a “sell” rating in a research report on Monday, March 3rd. Mizuho lifted their price target on Solventum from $70.00 to $82.00 and gave the company a “neutral” rating in a research report on Monday, March 3rd. Bank of America upped their price objective on shares of Solventum from $80.00 to $85.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 26th. Wells Fargo & Company lifted their target price on shares of Solventum from $73.00 to $75.00 and gave the company an “equal weight” rating in a research report on Friday, February 28th. Finally, Morgan Stanley increased their price target on shares of Solventum from $73.00 to $80.00 and gave the stock an “equal weight” rating in a report on Wednesday, March 5th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $79.86.

Solventum Trading Down 5.7 %

Shares of SOLV opened at $66.22 on Friday. Solventum Co. has a fifty-two week low of $47.16 and a fifty-two week high of $85.92. The firm has a market cap of $11.45 billion and a price-to-earnings ratio of 24.08. The firm has a 50 day moving average price of $75.42 and a 200-day moving average price of $71.95. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.83 and a current ratio of 1.15.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.